Literature DB >> 11432469

Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents.

R Schindler1.   

Abstract

Identification of inhibitors of retinyl ester hydrolase (REH) would help to elucidate its role in vitamin A metabolism in vivo. By using standard incubation conditions, the effects of 215 drugs as potential inhibitors of purified pig and human liver REH when acting on micellar substrate retinyl palmitate were evaluated at 16.7, 167, and 1670 microM. Out of the compounds tested, 103 were inhibitors of the pig liver enzyme. The most potent compounds, in order of decreasing activity, were chloral hydrate, lovastatin, phytomenadione, alimemazine, physostigmine, thioridazine, phenoxybenzamine, probucol, cinnarizine, cyclandelate, amiodarone, flupenthixol, and naftidrofuryl; this order is roughly similar to that of their inhibition of human liver REH. Of the 10 tricyclic ring-containing drugs tested, alimemazine was the most potent enzyme inhibitor. The concentrations necessary for 50% enzyme inhibition ranged from <2.6 up to >540 microM. Moreover, inhibitory kinetic studies showed that at least two pharmaceuticals, chloral hydrate and amiodarone, are potent REH inhibitors at therapeutically achievable serum concentrations. First-pass metabolites were inactive as REH inhibitors compared to that of the parent compounds, in the cases of chloral hydrate, lovastatin, and cyclandelate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432469     DOI: 10.1007/s11745-001-0755-z

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  40 in total

1.  Kinetics of chlorambucil in vitro: effects of fluid matrix, human gastric juice, plasma proteins and red cells.

Authors:  K Löf; J Hovinen; P Reinikainen; L M Vilpo; E Seppälä; J A Vilpo
Journal:  Chem Biol Interact       Date:  1997-03-14       Impact factor: 5.192

2.  Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren.

Authors:  W Riess; H Stierlin; P Degen; J W Faigle; A Gérardin; J Moppert; A Sallmann; K Schmid; A Schweizer; M Sulc; W Theobald; J Wagner
Journal:  Scand J Rheumatol Suppl       Date:  1978

Review 3.  Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 4.  Lipidosis induced by amphiphilic cationic drugs.

Authors:  H Lüllmann; R Lüllmann-Rauch; O Wassermann
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

5.  Fluorometric determination of vitamin A in human blood and liver.

Authors:  J N Thompson; P Erdody; R Brien; T K Murray
Journal:  Biochem Med       Date:  1971-02

6.  Mathematical analysis of concentration-response relationships. Method for the evaluation of the ED50 and the number of binding sites per receptor molecule using the logit transformation.

Authors:  D Hafner; E Heinen; E Noack
Journal:  Arzneimittelforschung       Date:  1977

7.  Purification and characterization of retinyl ester hydrolase as a member of the non-specific carboxylesterase supergene family.

Authors:  R Schindler; R Mentlein; W Feldheim
Journal:  Eur J Biochem       Date:  1998-02-01

8.  Inhibition of chicken liver carboxylesterase by activated carbonyls and carbonyl hydrates.

Authors:  M C Berndt; M R Bowles; G J King; B Zerner
Journal:  Biochim Biophys Acta       Date:  1996-12-05

9.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.

Authors:  C Olbricht; C Wanner; T Eisenhauer; V Kliem; R Doll; M Boddaert; P O'Grady; M Krekler; B Mangold; U Christians
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

10.  Specificity of purified monoacylglycerol lipase, palmitoyl-CoA hydrolase, palmitoyl-carnitine hydrolase, and nonspecific carboxylesterase from rat liver microsomes.

Authors:  R Mentlein; M Suttorp; E Heymann
Journal:  Arch Biochem Biophys       Date:  1984-01       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.